Trial Profile

A Global Multicenter, Open Label, Randomized Phase III Confirmatory Study of Lisaftoclax (APG-2575) in Combination With Acalabrutinib Versus Immunochemotherapy in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA-2)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 16 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Acalabrutinib (Primary) ; Chlorambucil (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Lisaftoclax (Primary) ; Rituximab (Primary)
Indications Chronic lymphocytic leukaemia
Focus Registrational; Therapeutic Use
Acronyms GLORA-2
Sponsors Ascentage Pharma

10 Dec 2024 According to Ascentage Pharma media release, company announced that it has released the latest clinical data of this trial in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
14 Apr 2024 Status changed from not yet recruiting to recruiting.
22 Mar 2024 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com